Plus Therapeutics (PSTV) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Plus Therapeutics faces a significant business risk following a notification from Nasdaq regarding non-compliance with continued listing requirements. The company’s stockholders’ equity fell below the mandated threshold, and despite submitting a compliance plan, assurance of Nasdaq’s acceptance or successful adherence to listing standards remains uncertain. If Plus Therapeutics’ common stock is delisted, it may lead to trading on less established markets, negatively impacting stock liquidity, capital access, and potentially reducing the stock’s market price.
The average PSTV stock price target is $18.00, implying 700.00% upside potential.
To learn more about Plus Therapeutics’ risk factors, click here.
